Abstract: Provided are novel tumor-specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize tumor-associated antigens and that are obtained from a tumor patient who shows at least partial clinical response or is symptom-free. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of tumors are described.

Abstract: The present invention provides for chimeric Wnt antagonists comprising a Frz domain component derived from a Frizzled protein, a secreted Frizzled related protein or Ror protein and an Fc immunoglobulin component, and their use in the treatment and diagnostic detection of cellular Wnt signaling and Wnt-mediated disorders, including cancer.

Abstract: The present invention relates to a cytotoxic composition that contains, as an active ingredient, an IgG antibody produced in eggs of a transgenic avian with a gene encoding the IgG antibody. The IgG antibody is expected to produce high anti-tumor effects with less side-effects because this antibody has higher CDC activity than that of the corresponding CHO cell-derived IgG antibody and its primary protein structure is not altered. The present invention also provides an agent for ameliorating or treating a cancer and an agent for treating an autoimmune disease, which contain the cytotoxic composition.

Abstract: The invention features diagnostic and therapeutic methods and compositions featuring androgen receptor variant proteins and nucleic acid molecules whose expression is increased in androgen related diseases or disorders.

Abstract: To gain a better understanding of tumor angiogenesis endothelial cells (ECs) were isolated and gene expression patterns were evaluated. When transcripts from ECs derived from normal and malignant colorectal tissues were compared with transcripts from non-endothelial cells, over 170 genes predominantly expressed in the endothelium were identified. Comparison between normal- and tumor-derived endothelium revealed differentially expressed genes, including many that were specifically elevated in tumor-associated endothelium. Experiments with representative genes from this group demonstrated that most were similarly expressed in the endothelium of primary lung, breast, brain, and pancreatic cancers as well as in metastatic lesions of the liver. These results demonstrate that neoplastic and normal endothelium in humans are distinct at the molecular level.

Abstract: The present technology relates to genetic products the expression of which is associated with cancer diseases. The present technology also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.

Abstract: Methods for diagnosing prostate cancer, and differentiate prostate cancer from other prostate complications, and use of said method, and diagnosing and monitoring lymph gland metastasis, post operative examinations, and examinations during or after radiation, cytostatic, and androgen treatments are disclosed. The methods comprise injecting tracer-labelled PSA or hK2 specific antibodies, visualising PSA or hK2 producing tissue with the aid of a visualisation method, and diagnosing prostate cancer from the difference in visualisation.

Abstract: The invention relates to newly discovered nucleic acid molecules and proteins associated with breast cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers are provided.

Abstract: This invention relates to use of neuropilin-2 as a novel biomarker and therapeutic target for melanoma. The presence of neuropilin-2 can be used as a biomarker for diagnosing and detecting individuals suffering from or at risk for developing melanoma. Also described are methods of using neuropilin-2 to capture circulating melanoma cells. The present invention further relates to methods of treating an individual suffering from or at risk for developing melanoma with an agent that inhibits the activity of neuropilin-2.

Abstract: The invention relates to methods for treating a subject by manipulating ABCB5 on a cell as well as related products. The methods include methods of treating cancer using ABCB5 binding molecules such as antibodies and fragments thereof.

Abstract: This invention relates to antibodies with altered binding to FcRn, and particularly antibodies having enhanced binding to FcRn and/or enhanced serum half-lives. The invention also relates to methods of using the antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease.

Abstract: IMP-1 was abundantly expressed in the majority of lung-cancers examined. Positive immunostaining of IMP-1 was correlated with tumor size (pT-classification; P=0.0003), non-adenocarcinoma histology (P<0.0001), low-histological grade (P=0.0001), and poor prognosis (P=0.0053). Suppression of IMP-1 expression with siRNA effectively suppressed growth of NSCLC cells. IMP-1 was able to bind to mRNAs encoding a variety of proteins involved in signal transduction, cell-cycle progression, cell adhesion and cytoskeleton, and various types of enzymatic activities. These results suggest that IMP-1 expression is likely to play important roles in lung cancer development and progression, and that IMP-1 is a prognostic marker and a promising therapeutic target for treatment of lung cancer.

Abstract: The present invention provides novel human anti-cancer antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of cancer.

Abstract: The present invention relates to an antibody binding to Claudin6 (CLDN6) expressed on a cell membrane. The antibody of the present invention recognizes human CLDN6 present in a native form on cell membrane surface and exhibits cytotoxicity through ADCC and/or CDC activities against cancer cell lines highly expressing human CLDN6. Moreover, the antibody of the present invention has cell growth inhibitory effect through conjugation with toxin on cancer cell lines highly expressing human CLDN6. The human CLDN6 is overexpressed in tumor tissues (lung adenocarcinoma, gastric cancer, and ovarian cancer), although its expression is not observed in normal tissues. Thus, the anti-CLDN6 antibody is expected to highly accumulate in tumors highly expressing human CLDN6 and can serve as a very effective antitumor agent.

Abstract: The present invention relates to a tumor cell of the peripheral zone of a tumor and methods of providing such a tumor cell. Further provided is a method for identifying a molecular marker diagnostic for an infiltrative cancer, an antibody, which specifically binds to such molecular marker, a method for identifying a therapeutic compound effective against a metastatic/infiltrative cancer disease and the use of a tumor cell according to the invention.

Abstract: A method for inhibition of leukemic stem cells expressing IL-3R?; (CD 123), comprises contacting the cells with an antigen binding molecule comprising a Fc region or a modified Fc region having enhanced Fc effector function, wherein the antigen binding molecule binds selectively to IL-3R? (CD123). The invention includes the treatment of a hematologic cancer condition in a patient by administration to the patient of an effective amount of the antigen binding molecule.

Abstract: The present invention provides methods to determine the likelihood of effectiveness of an EGFR targeting treatment in a subject affected with a tumor based on the expression of EGFR of endothelial cells associated with the tumor. The present invention also provides methods of treating a subject affected with, or at risk for developing cancer with an EGFR targeting treatment and methods to screen for an EGFR targeting treatment.

Abstract: The present invention concerns antibodies that neutralize at least one biological activity of pleiotrophin. The antibodies can inhibit cancer cell growth and angiogenesis in vitro or in vivo. The present invention provides for methods of inhibiting cancer cell growth or angiogenesis in a subject comprising administering to said subject an effective amount of the antibodies described herein. The present invention also provides for methods of making the neutralizing antibodies described herein.

Abstract: The invention relates to methods involving MS4A12 and agents targeting MS4A12 which are useful for therapy, diagnosis and testing of disease states, in particular cancer diseases. In particular, the invention relates to agents which reduce or inhibit expression or activity of MS4A12, compositions containing these agents, and methods for reducing, determining, or increasing the responsiveness of a cell towards EGF.

Abstract: Novel compounds, compositions and methods comprising modified antibodies are provided. In preferred embodiments the disclosed modified antibodies comprise antibodies having one or more of the constant region domains altered or deleted to afford beneficial physiological properties such as enhanced target localization and rapid blood clearance. The disclosed compounds are particularly useful for the treatment of neoplastic disorders in myelosuppressed patients.

Abstract: Disclosed are methods for diagnosing cancer in a test cell sample or fluid sample by detecting an increase in the level of expression of SLC7A5 in the test cell sample or fluid sample as compared to the level of expression of SLC7A5 in a control cell sample or fluid sample isolated from a normal subject.

Abstract: The present invention concerns methods and compositions for stably tethered structures of defined compositions with multiple functionalities and/or binding specificities. Particular embodiments concern stably tethered structures comprising a homodimer of a first monomer, comprising a dimerization and docking domain attached to a first precursor, and a second monomer comprising an anchoring domain attached to a second precursor. The first and second precursors may be virtually any molecule or structure, such as antibodies, antibody fragments, antibody analogs or mimetics, aptamers, binding peptides, fragments of binding proteins, known ligands for proteins or other molecules, enzymes, detectable labels or tags, therapeutic agents, toxins, pharmaceuticals, cytokines, interleukins, interferons, radioisotopes, proteins, peptides, peptide mimetics, polynucleotides, RNAi, oligosaccharides, natural or synthetic polymeric substances, nanoparticles, quantum dots, organic or inorganic compounds, etc.

Abstract: Provided are a composition for diagnosing cancer or screening an anticancer drug comprising an FLJ25416 gene or an antibody directed to a protein expressed from the FLJ25416 gene, a composition for treating cancer comprising an inhibitor of the gene or an inhibitor of the protein expressed from the gene and a pharmaceutically acceptable carrier, and a kit for diagnosing cancer comprising at least one of the FLJ25416 gene and the protein expressed from the FLJ25416 gene. The FLJ25416 gene is expressed at high level in specific cancer cells, and induces an increase in proliferation rate of normal cells. The expression of the gene is suppressed, which results in an inhibitory effect on cancer cell growth. Thus, the FLJ25416 gene can be used as a target gene for diagnosis or treatment of cancer.

Abstract: The present invention relates to reagents and methods for the detection of osteopontin fragments and distinguishing them from each other and from the full-length osteopontin protein. The present invention also relates to assays for the determination of the presence of osteopontin fragments in samples obtained from subjects and, further, the correlation of osteopontin fragment levels fragment levels with disease detection, progression and prognosis.

Abstract: Provided are novel human tumor-specific antibodies as well as fragments, derivatives and variants thereof that recognize tumor-associated antigen NY-ESO-1. In addition, pharmaceutical compositions comprising such antibodies and mimics thereof in the treatment of tumors are described.

Abstract: The invention provides LM-1 antibodies, functional fragments, modified and variant forms, nucleic acid and other compositions. The invention also provides antibodies, functional fragments, modified and variant forms that bind to LM-1 antigen (e.g., NONO/nmt55). Antibodies, functional fragments, modified and variant forms, nucleic acid and other compositions are useful in treatment and diagnostic methods. One method includes treating metastasis of a neoplasia, tumor or cancer in a subject in need of treatment by administering to the subject an amount of a LM-1 antibody, an antibody that binds to LM-1 antigen, or a functional fragment thereof, effective to treat metastasis of the neoplasia, tumor or cancer in the subject.

Abstract: A remedy for cancer obtained from a different viewpoint from the viewpoints employed in developing the existing anticancer drugs, i.e., focusing on the intercellular adhesion of cancer cells. Namely, provided is a remedy for cancer with fewer side effects which inhibits the proliferation of cancer cells and the intercellular adhesion of cancer cells. Also provided is an antibody, which recognizes the disintegrin domain of ADAM-15 and is usable as an anticancer agent, and so on. An antibody, which recognizes the disintegrin domain of ADAM-15 but does not recognize the RGD sequence or loop region in the disintegrin domain of ADAM-15, and so on; an antibody, which inhibits ADAM-15 and integrin ?v?3-dependent cell adhesion, and so on; and an antibody, which inhibits ADAM-15 and integrin ?v?1-dependent cell adhesion, and so on.

Abstract: A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. We have developed a xenograft model in which we have been able to establish tumors from primary tumors via injection of tumors in the mammary gland of severely immunodeficient mice. These xenograft assay have allowed us to do biological and molecular assays to characterize clonogenic solid tumor stem cells. We have also developed evidence that strongly implicates the Notch pathway, especially Notch 4, as playing a central pathway in carcinogenesis.

Abstract: Disclosed are antibodies that bind to Epithelial Cell Adhesion Molecule (EpCAM) and display certain advantages over known antibodies which bind to EpCAM, for example, the antibodies of the invention show good affinity, good cross-reactivity profiles and excellent ADCC and CDCC activity. Antibodies comprising specific heavy and light chain CDRs are disclosed. The invention thus relates to these antibodies and all uses thereof, in particular in the treatment of cancer. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer. Advantageous immunoconjugate compositions and methods using the new anti-EpCAM antibodies are also provided.

Abstract: The present application provides the amino acid and nucleic acid sequences of heavy and light chain complementarity determining regions of a cancer specific antibody directed to an epitope of variant Heterogeneous Ribonucleoprotein G (HnRNPG). In addition, the application provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or label, and methods of uses thereof. The application also relates to diagnostic methods and kits using the cancer specific antibodies disclosed herein. Further, the application provides novel cancer-associated epitopes and antigens of variant HnRNPG, and uses thereof.

Abstract: Provided are new tumor-associated antigens, binding molecules that specifically bind to the antigens, nucleic acid molecules encoding the binding molecules, compositions comprising the binding molecules, and methods of identifying or producing the binding molecules. The tumor-associated antigens are expressed on cancer cells and binding molecules capable of specifically binding to the antigens can be used in the diagnosis, prevention and/or treatment of cancer.

Abstract: The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies that specifically recognize and bind to specific epitopes from a range of ?-amyloid proteins. The antibodies of the present invention are particularly useful for the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system, particularly associated with amyloid-beta-related pathological abnormalities/changes in the tissues of the visual system.

Abstract: Proteins useful in the diagnosis of proliferative disorders of the colon are present in nuclear matrix protein preparations and can be characterized by molecular weight, isoelectric point, and amino acid sequence. The proteins may be identified, for example, by 2D-gel electrophoresis or by specific binding partners, such as antibodies.

Abstract: The present invention relates to a nucleic acid molecule encoding a polypeptide, wherein the polypeptide comprises (a) a first immunoglobulin domain comprising a VL domain linked to a VH domain, wherein the immunoglobulin domain specifically binds to an antigen expressed on tumour cells; (b) a second immunoglobulin domain comprising a VL domain linked to a VH domain, wherein the immunoglobulin domain specifically binds to an antigen expressed on tumour cells; and (c) a third immunoglobulin domain comprising a VL domain linked to a VH domain, wherein the immunoglobulin domain specifically binds to an effector cell antigen, wherein the effector cell is selected from the group consisting of NK cells, T cells, neutrophilic granulocytes, monocytes and macrophages; wherein at least one of the antigens expressed on tumour cells and bound by the immunoglobulin domain of (a) or (b) is an antigen expressed on tumour stem cells and/or on tumour precursor or progenitor cells; and wherein the ratio of immunoglobulin domai

Abstract: The present invention provides methods and compositions for treatment, screening, diagnosis, prognosis and therapy of breast cancer, colorectal cancer, esophageal cancer, gastric cancer, prostate cancer and uterine cancer, for monitoring the effectiveness of breast cancer, colorectal cancer, esophageal cancer, gastric cancer, prostate cancer and uterine cancer treatment, and for drug development.

Abstract: BST2 antibodies were selected by using as an indicator the binding between BST2 antibodies and various splicing variants of human BST2 antigen. As a result, the present inventors successfully obtained BST2 antibodies that specifically recognize BST2D, which has been reported to be expressed at high levels in cancer cells. The antibodies of the present invention specifically bind to cells expressing BST2D. Non-specific antibody binding to non-target tissues, which results in the decrease of antibody concentration in blood, can be prevented by using the antibodies of the present invention therapeutically. Alternatively, the present invention provides diagnostic agents comprising an antibody of the present invention, which specifically detect tissues expressing BST2D.

Abstract: The invention provides a method for testing a WT1-related disease, such as leukemia, a solid cancer, or an atypia, for diagnosing the disease, evaluating the course of cure and the prognosis of the disease more simply with high reliability, the method comprises measuring the amount of antibody against WT1 in a sample and using the measurement value and the time course of the value as a clinical marker for the testing.

Abstract: In some aspects, the invention provides a genetically tractable in situ non-human animal model for hepatocellular carcinoma. The model is useful, inter alia, in understanding the molecular mechanisms of liver cancer, in understanding the genetic alterations that lead to chemoresistance or poor prognosis, and in identifying and evaluating new therapies against hepatocellular carcinomas. The liver cancer model of this invention is made by altering hepatocytes to increase oncogene expression, to reduce tumor suppressor gene expression or both and by transplanting the resulting hepatocytes into a recipient non-human animal. The present invention also provides methods for identifying and validating tumor suppressor genes by screening pools of shRNAs that target genomic regions deleted in human cancers, such as human hepatocellular carcinomas.

Abstract: The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusion proteins that are useful for the treatment and diagnosis of various cancers, including colon cancer.

Abstract: Proteins that bind to matrix metalloproteinase 14 and methods of using such proteins are described.

Abstract: The present invention relates to a selectively soluble polymer capable of binding to one or more constituents in a mixture containing various biological materials and the methods of using such a polymer to purify a biomolecule from such a mixture. The polymer is soluble in the mixture under a certain set of process conditions such as pH or temperature and is rendered insoluble and precipitates out of solution upon a change in the process conditions. While in its solubilized state, the polymer is capable of binding to a selected entity within the stream such as impurities (DNA, RNA, host cell protein, endotoxins, etc) in a cell broth and remains capable of binding to that entity even after the polymer is precipitated out of solution. The precipitate can then be filtered out from the remainder of the stream and the desired biomolecule is recovered and further processed.

Abstract: Provided are compositions, methods, and kits relating to the detection of a circulating or soluble form of the KET receptor tyrosine kinase.

Abstract: The present invention relates to novel antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prostate cancer. Furthermore the present invention relates to assay systems and kits for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof.

Abstract: This invention relates to agents capable of reducing the activity, amount or density of complement regulatory proteins (CRPs) on target cells. The invention also provides methods of identification of such agents, methods of making, and uses thereof.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: Disclosed are: a method for activating a helper T cell, which comprises the step of adding a WT1 peptide to an antigen-presenting cell to activate the helper T cell, wherein the WT1 peptide is capable of binding to any one selected from an HLA-DRB1*1501 molecule, an HLA-DPB1*0901 molecule and an HLA-DPB1*0501 molecule; a composition for use in the method; a therapeutic and/or prophylactic method for cancer by activating a helper T cell; a pharmaceutical composition for use in the therapeutic and/or prophylactic method; and others.

Abstract: An antibody that binds to Mucin17 (Muc17) is disclosed. The antibody of the present invention preferably binds to the peptide of SEQ ID NO:3 and does not bind to the peptide of SEQ ID NO:4 or the peptide of SEQ ID NO:5. Also disclosed are an anti-cancer agent, preferably an anti-cancer agent for pancreatic cancer, which comprises the antibody of the present invention, as well as a method of diagnosing cancer using the antibody of the present invention, preferably the antibody of the present invention that does not bind to the secreted-form of Muc17.

Abstract: Compositions and methods are disclosed for improving the effectiveness of a chemotherapeutic regimen to eradicate multidrug-resistant transformed cells from the body of a mammal, preferably from the body of a human. The present disclosure capitalizes on the discovery of a novel multidrug-resistance associated protein (MRP), herein designated MRP-?. The disclosed compositions include MRP-? nucleic acids, including probes and antisense oligonucleotides, MRP-? polypeptides and antibodies, MRP-? expressing host cells, and non-human mammals transgenic or nullizygous for MRP-?. The disclosed methods include methods for attenuating aberrant MRP-? gene expression, protein production and/or protein function. In addition, methods are disclosed for identifying and using a modulator, such as an inhibitor, of MRP-?. Preferably, the modulator is a small molecule.

Abstract: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Ovr110) antibodies that internalize upon binding to Ovr110 on a mammalian in vivo. The invention also encompasses compositions comprising an anti-Ovr110 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr110 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr110 antibodies. The invention encompasses a method of producing the anti-Ovr110 antibodies. Other aspects of the invention are a method of killing an Ovr110-expressing cancer cell, comprising contacting the cancer cell with an anti-Ovr110 antibody and a method of alleviating or treating an Ovr110-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Ovr110 antibody to the mammal.

Abstract: The invention provides Cripto blocking antibodies, or biologically functional fragments thereof, and uses thereof. Antibodies which bind Cripto and modulate Cripto signaling are provided. Antibodies which bind Cripto and block the interaction between Cripto and ALK4 are provided. Antibodies which bind Cripto and modulate tumor growth are also provided. Antibodies which bind Cripto, modulate signaling, and modulate tumor growth are also provided. Antibodies which bind Cripto, block the interaction between Cripto and ALK4 and modulate tumor growth are provided. The invention also provides methods of using these antibodies in therapeutic, diagnostic, and research applications.